Journal: Cell reports

Article Title: T cell-specific P2RX7 favors lung parenchymal CD4 + T cell accumulation in response to severe lung infections

doi: 10.1016/j.celrep.2023.113448

Figure Lengend Snippet: CD4-KO ( Cd4 −/− ) mice were infected with ~100 CFU of Mbv MP287. Non-infected and infected CD4-KO mice were used as controls. At day 5 p.i., mice received splenic CD4 + T cells (1 × 10 6 ) from WT and P2RX7-KO ( P2rx7 −/− ) mice. (A) Experimental protocol ( BioRender.com ). (B) Average body weights (percentages related to day 0). (C) Lung weights/mice. (D) Lung CFU numbers. (E) Macroscopic images of right upper lung lobes. Scale bar, 1 cm. (F) Representative lung sections stained with H&E. Scale bars, 500 μm. (G) Left: flow-cytometry plots of CD44 and CD45i.v. on CD4 + T cells. Right: average frequencies of CD45i.v. + and CD45i.v. − cells in CD44 + CD4 + T cells. (H) Average numbers of CD44 + CD4 + T cells in the medLNs. (I) Representative confocal images of CD4, IFN-γ, and S100A9 expression in infected lung tissues. Scale bars, 50 μm. Data from three independent experiments, n = 3–5/experimental group per experiment. Data shown as means ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, one-way ANOVA (Tukey post tests) (C, D, and G) or unpaired t tests (B and H).

Article Snippet: Subsequently, the sections were blocked with 2% BSA in PBS for 30 min, and then incubated overnight at 4°C with primary anti-S100A9 antibody (Bio-Techne).

Techniques: Infection, Staining, Flow Cytometry, Expressing

Journal: Cell reports

Article Title: T cell-specific P2RX7 favors lung parenchymal CD4 + T cell accumulation in response to severe lung infections

doi: 10.1016/j.celrep.2023.113448

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: Subsequently, the sections were blocked with 2% BSA in PBS for 30 min, and then incubated overnight at 4°C with primary anti-S100A9 antibody (Bio-Techne).

Techniques: Virus, Recombinant, Saline, Cell Isolation, Isolation, Software

Journal: iScience

Article Title: Epithelial–stromal cell interactions and extracellular matrix mechanics drive the formation of airway-mimetic tubular morphology in lung organoids

doi: 10.1016/j.isci.2021.103061

Figure Lengend Snippet:

Article Snippet: Yellow fluorescence protein (pLEX_970_puro_DEST_YFP gifted by William Hahn (Addgene plasmid # 45295)) and mCherry (plv_mCherry gifted by Pantelis Tsoulfas, (Addgene plasmid # 36084)) plasmid in transfected bacteria were amplified and extracted with Qiagen Maxiprep kit (Qiagen, Manchester, UK).

Techniques: Virus, Fluorescence, Plasmid Preparation, Transfection, Bacteria, Recombinant, Modification, Cell Culture

Journal: Cells

Article Title: 4-Methylumebelliferone Enhances Radiosensitizing Effects of Radioresistant Oral Squamous Cell Carcinoma Cells via Hyaluronan Synthase 3 Suppression

doi: 10.3390/cells11233780

Figure Lengend Snippet: Effects of St -Hyal treatment or HAS3 knockdown on RR cells. ( A ) Protein expression analysis of siRNA-HAS3 transfection via Western blotting. Representative images of immunoblots are shown. Actin was used as a loading control, and the relative values of the HAS3/actin ratio are presented. For the HAS3 proteins, both bands were quantified together. ( B , C ) Logarithmic surviving fraction of each cell line treated with ( B ) 100 TRU/mL St -Hyal and IR or ( C ) HAS3 knockdown and IR. ( D ) Representative histograms of each cell line treated with 100 TRU/mL St -Hyal or with HAS3 knockdown. ( E ) Relative MFI of CD44 of each cell line treated with 100 TRU/mL St -Hyal or with HAS3 knockdown. ( F ) Relative SOD production levels of each cell line treated with HAS3 knockdown and IR. The SOD production levels of IR alone, HAS3 knockdown, and combined treatment groups were standardized based on the SOD level of the control group; * and ** indicate p < 0.05 and p < 0.01 vs. control, respectively; # and ## indicate p < 0.05 and 0.01 vs. 2 Gy, respectively.

Article Snippet: Small interfering RNA (siRNA) against HAS3 (sc-45295), the corresponding scrambled control siRNA (sc-37007), and anti-HAS3 (sc-365322) monoclonal primary antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA).

Techniques: Knockdown, Expressing, Transfection, Western Blot, Control